GW Pharmaceuticals PLC Holding(s) in Company (0174C)
June 23 2016 - 2:30AM
UK Regulatory
TIDMGWP
RNS Number : 0174C
GW Pharmaceuticals PLC
23 June 2016
TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARES(i)
1. Identity of the issuer or GW Pharmaceuticals PLC
the underlying issuer
of existing shares to which
voting rights are
attached: (ii)
----------------------------------------------------------- ---------------------------
2 Reason for the notification (please tick the appropriate
box or boxes):
----------------------------------------------------------------------------------------
An acquisition or disposal of voting rights
------------------------------------------------------------ --------------------------
An acquisition or disposal of qualifying financial X
instruments which may result in the acquisition
of shares already issued to which voting rights
are attached
------------------------------------------------------------ --------------------------
An acquisition or disposal of instruments with
similar economic effect to qualifying financial
instruments
------------------------------------------------------------ --------------------------
An event changing the breakdown of voting rights
------------------------------------------------------------ --------------------------
Other (please
specify):
---------------------------------------------------------- --------------------------
3. Full name of person(s) Scopia Capital Management
subject to the LP
notification obligation:
(iii) Scopia Management, Inc.
----------------------------------------------------------- ---------------------------
4. Full name of shareholder(s) Goldman Sachs & Co.
(if different from 3.):(iv)
----------------------------------------------------------- ---------------------------
5. Date of the transaction 20 June 2016
and date on
which the threshold is
crossed or
reached: (v)
----------------------------------------------------------- ---------------------------
6. Date on which issuer 22 June 2016
notified:
----------------------------------------------------------- ---------------------------
7. Threshold(s) that is/are
crossed or
reached: (vi, vii) 5%
----------------------------------------------------------- ---------------------------
8. Notified details:
--------------------------------------------------------------------------------------------------------
A: Voting rights attached to shares (viii, ix)
--------------------------------------------------------------------------------------------------------
Class/type Situation previous Resulting situation after the
of to the triggering triggering transaction
shares transaction
if possible
using
the ISIN
CODE
-------------- ------------------------------ --------------------------------------------------------
Number Number Number Number of voting % of voting
of of of shares rights rights (x)
Shares Voting
Rights
-------------- -------------- -------------- ------------- -------------------- -------------------
Direct Direct Indirect Direct Indirect
(xi) (xii)
-------------- ------------ ------------ ------------- -------- ---------- -------- ---------
Not
Applicable
-------------- -------------- ------------- -------- ---------- -------- ---------
B: Qualifying Financial Instruments
--------------------------------------------------------------------------------------------------------
Resulting situation after the triggering transaction
--------------------------------------------------------------------------------------------------------
Type of Expiration Exercise/ Number of voting % of voting
financial date Conversion rights that rights
instrument (xiii) Period (xiv) may be
acquired if
the
instrument
is
exercised/
converted.
---------------- ------------- ----------------------------- ------------------- -------------------
American
Depositary
Receipts Not
US36197T1034 Applicable Not Applicable 13,802,724 5.25%
---------------- ------------- ----------------------------- ------------------- -------------------
C: Financial Instruments with similar economic effect
to Qualifying Financial Instruments (xv, xvi)
--------------------------------------------------------------------------------------------------------
Resulting situation after the triggering transaction
--------------------------------------------------------------------------------------------------------
Type of Exercise Expiration Exercise/ Number of voting % of voting
financial price date Conversion rights instrument rights (xix,
instrument (xvii) period refers to xx)
(xviii)
--------------- ------------- ------------- -------------- -------------------- -------------------
Not Applicable Nominal Delta
--------------- ------------- ------------- -------------- -------------------- -------- ---------
Total (A+B+C)
--------------------------------------------------------------------------------------------------------
Number of voting rights Percentage of voting rights
----------------------------------------------- -------------------------------------------------------
13,802,724 5.25%
----------------------------------------------- -------------------------------------------------------
9. Chain of controlled undertakings through which the
voting rights and/or the
financial instruments are effectively held, if applicable:
(xxi)
----------------------------------------------------------------------------------
Scopia Capital Management LP is the investment manager
of certain funds that beneficially own the financial
instruments disclosed in Section 8 of this form and
which controls the voting rights attached those financial
instruments.
Scopia Management, Inc. is the general partner of Scopia
Capital Management LP
Proxy Voting:
----------------------------------------------------------------------------------
10. Name of the proxy holder: Not Applicable
--------------------------------------------- -----------------------------------
11. Number of voting rights proxy
holder will cease to hold:
--------------------------------------------- -----------------------------------
12. Date on which proxy holder will
cease to hold voting rights:
--------------------------------------------- -----------------------------------
13. Additional information:
------------------------------------------- -------------------------------------
14. Contact name: Samantha Nasello, Chief Compliance
Officer
------------------------------------------- -------------------------------------
15. Contact telephone number: +1.212.370.0304
------------------------------------------- -------------------------------------
This information is provided by RNS
The company news service from the London Stock Exchange
END
HOLEAPKAAESKEFF
(END) Dow Jones Newswires
June 23, 2016 02:30 ET (06:30 GMT)
Gw Pharmaceuticals (LSE:GWP)
Historical Stock Chart
From Jun 2024 to Jul 2024
Gw Pharmaceuticals (LSE:GWP)
Historical Stock Chart
From Jul 2023 to Jul 2024